About the Journal
AIMS & SCOPE
HemaSphere publishes results of
highly relevant basic, translational, and clinical research in hematology. We are especially looking for strong studies reporting novel findings that are of high impact to the field of hematology.
Review articles, guideline articles, and controversy articles provide clear overviews and discussions of new developments as well as recommendations for patient care.
HemaSphere is the
premier hematology information resource, which is covered by the HemaTopics section in the journal. This section provides insightful discussions on all aspects related to hematology, including summaries of important articles, reports of new therapies, discussions on European policy, and other hematology news items.
HemaSphere is an
open access journal, powered by the
European Hematology Association, and dedicated to
supporting hematology patient care, research, and education worldwide.
HemaSphere is fully indexed in PubMed Central (PMC), in Scopus, and in the following
Clarivate Analytics products and categories:
SCIENCE CITATION INDEX EXPANDED (SCIE) - Hematology
CC/CLINICAL MEDICINE - Hematology
Essential Science Indicators - Clinical Medicine
CITATION METRICS & IMPACT FACTOR
is proud to be indexed in Scopus with a CiteScore of 5.4 (April 2022). CiteScore is using a 4-year window to track citations and is updated monthly.
As a newer journal,
HemaSphere does not yet have an Impact Factor, but citations are being tracked and are available in the Web of Science. Clarivate recently completed an evaluation of
HemaSphere using the Web of Science selection criteria, and their editors found
HemaSphere continues to meet quality criteria and
now also meets impact criteria. As such,
HemaSphere is expecting its first impact factor in June 2022.
Journals that are accepted in to SCIE and/or SSCI before January 1st and that remain covered in one of these collections when JCR production is started in March, are eligible to appear in the following June release of the JCR data and receive a
Journal Impact Factor™ (JIF), ie, in June 2022.
Coverage will begin with Volume 3, 2019.
PUBLICATION & EDITORIAL STAFF CONTACTS
Lead Publisher, Open Access
Editorial Manager, European Hematology Association
Tori Kronz[email protected]
For journal specific contacts go to
media kit site
Go to the article and use the Content & Permissions link under Article Tools
Translations Rights & Licensing
Reprints and Special Projects (U.S./Canada)
For journal specific contacts go tomedia kit site
Reprints and Special Projects (non-U.S./Canada)
[email protected] and for journal specific contacts go to
media kit site
Tarryn Greenberg, Lead Publisher
Phone: +44 203 197 6707
LWW Business Offices
EHA Executive Offic
Citi Building, 41st Floor
25 Canada Square
London E14 5LQ
Tel: +44 (0)20 3197 6500
Fax: +44 (0)20 3197 6501
2514 AA - The Hague
Tel: +31 (0)70 3020 099 [email protected]